Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study

Detalles Bibliográficos
Autores principales: Ho, Stephanie L., Niu, Fang, Pola, Suresh, Velayos, Fernando S., Ning, Xian, Hui, Rita L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211201/
https://www.ncbi.nlm.nih.gov/pubmed/32253718
http://dx.doi.org/10.1007/s40259-020-00423-0
Descripción
Sumario:

Ejemplares similares